From the Journals

Ginger for migraine: A new review


 

FROM THE JOURNAL OF CLINICAL PSYCHIATRY

‘Good additional tool’

Commenting on the study for this news organization, Jessica Ailani, MD, director, MedStar Georgetown Headache Center and professor of clinical neurology, MedStar Georgetown University Hospital, Washington, said that for “people with migraine who are seeking treatment with minimal side effects that they can obtain without counsel of a health care provider, ginger is a good additional tool to have.”

Dr. Ailani, vice cochair of strategic planning in the MedStar department of neurology, who was not involved with the study, said that clinicians can “consider suggesting ginger to patients with migraine that have associated nausea who are interested in nonpharmacologic ways to treat symptoms.”

Since there are “many other effective ways to treat migraine,” she advises “conversing with the patient about speed of onset of efficacy, along with tolerability, and return of migraine symptoms as important factors to evaluate when choosing and staying with a treatment.”

Also commenting on the study for this news organization, Nada Hindiyeh, MD, clinical associate professor, department of neurology, Stanford (Calif.) University, called it a “nice summary of the objective research available for the use of ginger in acute and preventive treatment of migraine.”

Although there is insufficient literature evaluating ginger alone in migraine treatment, so “no definitive conclusions can be drawn,” since it appears to be safe and “somewhat helpful for migraine-associated nausea and vomiting and possibly in frequency of migraine reduction, it remains a considerable alternative for those seeking nonprescription options,” said Dr. Hindiyeh, who was not involved with the study.

Dr. Andrade publishes an e-newsletter supported by Sun Pharmaceuticals, with payments made to charities. He has received payments for developing educational materials for scientific initiatives and programs. Dr. Ailani reports honoraria for independent consulting from various pharmaceutical companies and clinical trial grants to her institution from the American Migraine Foundation, Allergan, Biohaven, Eli Lilly, Satsuma, and Zosano. Dr. Hindiyeh discloses no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Ferric carboxymaltose calms restless legs
MDedge Psychiatry
Short-acting opioids needed for withdrawal in U.S. hospitals, say experts
MDedge Psychiatry
AAN issues ethical guidance on controversial Alzheimer’s drug
MDedge Psychiatry
New blood test may detect preclinical Alzheimer’s years in advance
MDedge Psychiatry
Visual snow: Alarming and not uncommon
MDedge Psychiatry
Record-breaking autism rates reported with new CDC criteria
MDedge Psychiatry
Is mindfulness key to helping physicians with mental health?
MDedge Psychiatry
Could Viagra help prevent Alzheimer’s?
MDedge Psychiatry
‘Alarming’ rate of abuse in pregnant women with epilepsy
MDedge Psychiatry
New insights into psychogenic seizures in teens
MDedge Psychiatry